SCHEMBL1339008

SCHEMBL1339008

O=C(c1cnccc1Cl)N1CCOCC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.60
MAPT P10636 1/20 0.54
TSHR P16473 1/20 0.54
HTT P42858 1/20 0.54
HSP90AA1 P07900 1/20 0.52
PHGDH O43175 1/20 0.50
PKM P14618 1/20 0.50
LMNA P02545 1/20 0.48
HPGD P15428 1/20 0.48
KMT2A Q03164 2/20 0.47
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA3 P07451 1/20 0.47
CA4 P22748 1/20 0.47
CA6 P23280 1/20 0.47
CA5A P35218 1/20 0.47
CA7 P43166 1/20 0.47
CA9 Q16790 1/20 0.47
CA13 Q8N1Q1 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24568978 0.86 HPGD (0.51) KDM4ETSHRHSP90AA1HPGDKMT2A
SCHEMBL16115398 0.80 HSP90AA1 (0.50) KDM4EMAPTTSHRHTTHSP90AA1
SCHEMBL17438946 0.79 HSP90AA1 (0.49) KDM4EMAPTTSHRHTTHSP90AA1
(2-Chlorophenyl)(Morpholino)Methanone SCHEMBL6938284 0.78 MGLL (0.68) KDM4EMAPTTSHRHTTHSP90AA1
SCHEMBL15754906 0.75 PHGDH (0.66) KDM4EMAPTTSHRHTTPHGDH
SCHEMBL1042677 0.75 KDM4E (1.00) KDM4EMAPTTSHRHTTHSP90AA1
SCHEMBL24568979 0.74 ALDH1A1 (0.47) PKMHPGD
SCHEMBL27402624 0.74 MAOB (0.57) KDM4EMAPTTSHRHTTHPGD
SCHEMBL16079573 0.74 KDM4E (0.75) KDM4EMAPTTSHRHTTHSP90AA1
(2-Chlorophenyl)(Morpholino)Methanone SCHEMBL4648775 0.74 MGLL (0.62) KDM4EMAPTTSHRHTTHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3218375-B1 SUBSTITUTED PYRROLOPYRDINES AS INHIBITORS OF BROMODOMAIN GENENTECH INC (US) 2022-04-27 EP disclosed
US-8063212-B2 Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer ELI LILLY AND COMPANY (US) 2011-11-22 US disclosed
EP-2125794-B1 IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER LILLY CO ELI (US) 2010-10-20 EP disclosed
US-20100081641-A1 IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER ELI LILLY AND COMPANY 2010-04-01 US disclosed
EP-2125794-A1 IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER Eli Lilly & Company (US) 2009-12-02 EP disclosed
WO-2008076705-A1 IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER ELI LILLY AND COMPANY (US) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081641-A1 IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER PLK1, AURKC, BUB1B KDM4E 659/4885MAPT 3407/4885TSHR 3564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.